Biogen Pharmachem Industries Ltd (531752)
சுருக்கம்
நிகழ்வுகள்
- சமீபத்திய முடிவுகள்
- Q2 FY27, தாக்கல் செய்யப்பட்டது 3 நவ. 2026
- இயக்குநர் குழுக் கூட்ட அறிவிப்பு
- 21 ஜூலை 2026
பங்குச் சந்தைத் தரவு. ஒவ்வொரு எண்ணும் அதன் சொந்தப் பக்கம் காட்டும் வடிவத்திலேயே; தேதிகள் தரவின் தேதிகள். தகவலுக்கு மட்டுமே, முதலீட்டு ஆலோசனை அல்ல.
📈 பங்கு விலை & நிகழ்வுகள்
Q2 FY27 முடிவுகள்
Biogen Pharmachem Industries Ltd reported Q2 FY27 results on 3 Nov 2026: revenue ₹0.0 Cr, and net profit ₹0.3 Cr (against a loss a year earlier).
| Q2 FY27 (₹ கோடி) | மதிப்பு | YoY Q2 FY26-உடன் | QoQ |
|---|---|---|---|
| வருவாய் | ₹0.0 | — | -100.0% |
| செயல்பாட்டு லாபம் | ₹-0.0 | நஷ்டம் குறைந்தது | நஷ்டமாக |
| நிகர லாபம் | ₹0.3 | நஷ்டத்திலிருந்து | +16.2% |
| EPS (₹) | 0.00 | — | — |
- திருப்பம்: ஓராண்டுக்கு முன் நஷ்டத்திற்கு மாறாக லாபம்
- முன்வரி லாபம் முழுவதும் பிற வருமானம் அல்லது ஒருமுறை வரும் பொருட்களிலிருந்தே வந்தது
- லாபம் இருந்தும் H1 FY27 செயல்பாட்டுப் பணப்புழக்கம் எதிர்மறையாக இருந்தது
லாபத்தின் தரம்: ₹0.3 கோடி வரிக்கு முந்தைய லாபத்தில் எதுவும் முக்கிய வணிகத்திலிருந்து வரவில்லை; அனைத்தும் பிற வருமானம் மற்றும் ஒருமுறை வரவுகளிலிருந்தே வந்தது.
📢 சமீபத்திய கார்ப்பரேட் அறிவிப்புகள்
Biogen Pharmachem Industries Ltd has submitted its quarterly statement of deviation or variation under Regulation 32(1) of SEBI LODR Regulations for the period ended September 30, 2026. The company confirmed that it has no unutilised funds remaining from any public, rights, preferential issues, or qualified institutional placements. Consequently, no deviation or variation was reported, and no Annexure-A statement was required to be submitted.
- Regulation 32(1) statement filed for the period ended September 30, 2026
- Reported zero remaining unutilised funds from past issue proceeds
- No deviation or variation reported under SEBI circular CIR/CFD/CMD1/162/2019
Biogen Pharmachem Industries reported its financial results for the quarter ended September 30, 2026, posting a net profit of ₹25.73 lakh compared to a net loss of ₹49.15 lakh in the corresponding quarter last year. Revenue from operations remained at nil, with all recorded top-line coming from other income of ₹28.33 lakh. For the first half (H1 FY27), net profit stood at ₹47.87 lakh against ₹85.33 lakh in H1 FY26. Total expenses for the quarter were contained at ₹2.61 lakh.
- Revenue from operations was nil, with total income driven entirely by other income of ₹28.33 lakh for Q2 FY27
- Net profit after tax stood at ₹25.73 lakh compared to a net loss of ₹49.15 lakh in Q2 FY26
- Total expenses for Q2 FY27 decreased to ₹2.61 lakh from ₹38.67 lakh in the prior-year period
- Paid-up equity share capital stood at ₹10,530.37 lakh with cash and cash equivalents at ₹1.27 lakh as of September 30, 2026
Rama Shiva Lease Finance Private Limited has disposed of its entire holding in Biogen Pharmachem Industries Limited via open market sale on October 16, 2026. The entity sold 4,25,83,333 equity shares, representing 4.04% of the company's total voting capital of 1,05,30,36,833 shares. Following this transaction, Rama Shiva Lease Finance holds zero shares and nil voting rights in the company. Biogen Pharmachem is a micro-cap entity trading at penny stock levels with a TTM revenue of Rs 2 Cr.
- Complete exit by Rama Shiva Lease Finance of 4,25,83,333 equity shares (4.04% stake)
- Sale executed through the open market on October 16, 2026
- Post-transaction holding reduced to 0 shares (0.00% voting capital)
- Total diluted share capital stands unchanged at 1,05,30,36,833 equity shares of Rs 1 each
Biogen Pharmachem Industries Ltd has issued the notice for its 31st Annual General Meeting scheduled for September 29, 2026, via video conferencing. Key ordinary business items include the adoption of FY26 audited financial statements, the reappointment of retiring director Mr. Kelash Bunkar, and the reappointment of statutory auditor M/s. Goenka Mehta & Associates until the 2031 AGM. The register of members and share transfer books will remain closed from September 22 to September 29, 2026.
- 31st AGM scheduled for Tuesday, 29th September 2026 at 4:00 PM IST via VC/OAVM
- Remote e-voting window opens on 26th September 2026 (09:00 AM) and closes on 28th September 2026 (05:00 PM)
- Cut-off date for voting eligibility set as Tuesday, 22nd September 2026
- Proposed reappointment of statutory auditors M/s Goenka Mehta & Associates (FRN: 129445W) from conclusion of this AGM until AGM in 2031
Biogen Pharmachem Industries has submitted its quarterly statement of deviation or variation for the period ending June 30, 2026. The company confirmed that it has no unutilized funds remaining from any past public, rights, or preferential issues, or Qualified Institutional Placements (QIP). As all previously raised capital has been fully deployed, the company reported no deviations from the objects stated in its offer documents. This is a routine compliance filing required under SEBI Regulation 32(1).
- Zero unutilized funds reported as of June 30, 2026
- No deviation or variation in the use of proceeds from past capital raises
- Filing covers all past public, rights, and preferential issues
- Compliance maintained with SEBI Circular dated 24th December, 2019
Biogen Pharmachem reported a net profit of ₹0.22 crore for the quarter ended June 30, 2026, marking a recovery from a loss of ₹0.36 crore in the previous quarter (Q4 FY26). However, the company's revenue from operations witnessed a sharp 71.2% year-on-year decline, falling to ₹0.44 crore from ₹1.54 crore in Q1 FY26. The return to profitability was primarily driven by a significant reduction in total expenses, which dropped to ₹0.22 crore from ₹0.94 crore in the preceding quarter. Despite the profit, the absolute scale of operations remains extremely small for a company with a ₹28 crore market cap.
- Revenue from operations fell 71.2% YoY to ₹44.34 lacs (₹0.44 cr) from ₹154.28 lacs.
- Net profit stood at ₹22.14 lacs (₹0.22 cr) compared to a loss of ₹35.88 lacs in the previous quarter.
- Total expenses were reduced by 76.3% sequentially to ₹22.20 lacs from ₹93.70 lacs.
- Paid-up equity share capital increased to ₹105.30 cr from ₹90.26 cr in the year-ago period.
- Earnings Per Share (EPS) remained negligible at ₹0.00 for the quarter.
Biogen Pharmachem Industries Ltd has scheduled a board meeting for August 5, 2026, to consider and approve the unaudited financial results for the quarter ended June 30, 2026. This is a routine regulatory filing for the micro-cap company, which has a market capitalization of Rs 30 Cr. The company reported a net loss of Rs 0.36 Cr in the previous quarter (March 2026) on revenue of Rs 0.58 Cr. Investors will be looking for signs of recovery given the TTM revenue is only Rs 1 Cr.
- Board meeting scheduled for August 5, 2026, to approve Q1 FY27 results
- Company reported a TTM revenue of only Rs 1 Cr against a net worth of Rs 99 Cr
- Operating profit margin remains highly volatile at -43.7% TTM
- Stock has seen a significant price decline of 59.9% over the last 12 months
நிறுவனச் சுயவிவரம்
நிதிச் செயல்திறன்
இந்த நிறுவனத்துக்கான நிதிப் பகுப்பாய்வுத் தரவு இன்னும் கிடைக்கவில்லை.
செயல்பாட்டு உந்துசக்திகள்
இந்த நிறுவனத்திற்கான செயல்பாட்டுப் பகுப்பாய்வுத் தரவு இன்னும் கிடைக்கவில்லை.
வியூக வளர்ச்சி
இந்த நிறுவனத்துக்கான வியூக வளர்ச்சிப் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
வெளிப்புறக் காரணிகள்
இந்த நிறுவனத்துக்கு வெளிப்புறக் காரணிகளின் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
ஒழுங்குமுறை & நிர்வாகம்
இந்த நிறுவனத்திற்கான ஒழுங்குமுறைப் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
அபாயப் பகுப்பாய்வு
இந்நிறுவனத்துக்கான அபாய பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
